Korean Pharma Accelerates Coronavirus-Related R&D, Calls For More Support
As South Korean companies jump into the development of vaccines and drugs for the coronavirus, they also call for stronger government support and increased collaboration between the state and private sectors.
You may also be interested in...
A South Korean pharma firm is set to soon begin pivotal clinical trials for a hyperimmune globulin for the treatment of COVID-19 patients and plans to commercialize the product this year, with a hope of outrunning rivals including Takeda.
Celltrion unveils emergency plans to deal with the COVID-19 situation in South Korea by speeding up development of a potential therapeutic antibody and rapid, accurate testing kit without considering economic returns.
If clinical trials prove it effective against COVID-19, remdesivir could potentially help millions of patients - which raises big questions about funding and access.